- 1. DEX/MORPH
- (UMLS (NCI) C0796475) Dextromethorphan/Morphine =Therapeutic or Preventive Procedure
| - 43. Dexamethasone/Methotrexate/Procarbazine/Teniposide
- (UMLS (NCI) C0279211) =Therapeutic or Preventive Procedure
|
- 2. DEXA
- [A technique for scanning bone and measuring bone mineral density (BMD). A DXA scanner produces 2 X-ray beams, each with different energy levels. One beam is high energy while the other is low energy. The amount of x-rays that pass through the bone is measured for each beam. This will vary depending on the thickness of the bone. Based on the difference between the 2 beams, the bone density can be measured. ( NCI )] (UMLS (NCI) C1510486) Dual Energy X-ray Absorptometry;
Dual X-Ray Absorptiometry;
Dual X-ray Absorptometry;
DXA =Diagnostic Procedure ;
| - 44. Dexamethasone/Methotrexate/Procarbazine/Vincristine
- (UMLS (NCI) C0281652) =Therapeutic or Preventive Procedure ;
|
- 3. Dexamethasone acetate
- [The acetate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) ( NCI )] (UMLS (NCI) C0057598) =Steroid; Pharmacologic Substance ;
=(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione;
=DEXAMETHASONE ACETATE MISC. POWDER (GM);
DEXAMETHASONE ACETATE 8 MG/ML;
DEXAMETHASONE ACETATE 16 MG/ML | - 45. Dexamethasone/Methotrexate/Thioguanine
- (UMLS (NCI) C0278918) =Therapeutic or Preventive Procedure
|
- 4. dexamethasone suppression test
- [injection of dexamethasone causes serum cortisol to fall; this can be correlated with behavioral measures of depression, but the test is not reliable enough for diagnostic use. ( CSP )] (UMLS (CSP) C0430115) =Laboratory Procedure =Administration of psychologic test;
| - 46. Dexamethasone/Methotrexate/Thioguanine/Vincristine
- (UMLS (NCI) C0796378) DM/MTX/TG/VCR =Therapeutic or Preventive Procedure ;
|
- 5. Dexamethasone/Dexniguldipine/Doxorubicin/Prednisone/Vincristine
- (UMLS (NCI) C0281631) =Therapeutic or Preventive Procedure
| - 47. Dexamethasone/Methotrexate/Thiotepa/Vincristine
- (UMLS (NCI) C0281370) =Therapeutic or Preventive Procedure
|
- 6. Dexamethasone/Dexniguldipine/Doxorubicin/Vincristine
- (UMLS (NCI) C0281632) =Therapeutic or Preventive Procedure
| - 48. Dexamethasone/Methotrexate/Vincristine
- (UMLS (NCI) C0879378) =Therapeutic or Preventive Procedure
|
- 7. Dexamethasone/Doxorubicin
- (UMLS (NCI) C1134562) =Therapeutic or Preventive Procedure ;
| - 49. Dexamethasone/Methotrexate/Zidovudine
- (UMLS (NCI) C0279010) =Therapeutic or Preventive Procedure ;
|
- 8. Dexamethasone/Doxorubicin/Interferon Alfa/Vincristine
- (UMLS (NCI) C0338098) =Therapeutic or Preventive Procedure ;
| - 50. Dexamethasone/Metoclopramide
- (UMLS (NCI) C0678001) =Therapeutic or Preventive Procedure
|
- 9. Dexamethasone/Doxorubicin/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine
- (UMLS (NCI) C0281125) =Therapeutic or Preventive Procedure
| - 51. Dexamethasone/Metoclopramide/Midazolam
- (UMLS (NCI) C0280664) =Therapeutic or Preventive Procedure
|
- 10. Dexamethasone/Doxorubicin/Methotrexate/Pegaspargase/Vincristine
- (UMLS (NCI) C0281121) =Therapeutic or Preventive Procedure
| - 52. Dexamethasone/Oblimersen
- (UMLS (NCI) C1134606) =Therapeutic or Preventive Procedure
|
- 11. Dexamethasone/Doxorubicin/Pegaspargase/Vincristine
- (UMLS (NCI) C0338243) =Therapeutic or Preventive Procedure
| - 53. Dexamethasone/Oblimersen/Thalidomide
- (UMLS (NCI) C1327807) =Therapeutic or Preventive Procedure ;
|
- 12. Dexamethasone/Doxorubicin/Prednisone/Quinine/Vincristine
- (UMLS (NCI) C0281414) =Therapeutic or Preventive Procedure
| - 54. Dexamethasone/Ondansetron
- (UMLS (NCI) C0935854) =Therapeutic or Preventive Procedure
|
- 13. Dexamethasone/Doxorubicin/Prednisone/Vincristine
- (UMLS (NCI) C0281415) =Therapeutic or Preventive Procedure
| - 55. Dexamethasone/Pegaspargase
- (UMLS (NCI) C0935861) =Therapeutic or Preventive Procedure ;
|
- 14. Dexamethasone/Doxorubicin/PSC 833/Vincristine
- (UMLS (NCI) C0392978) =Therapeutic or Preventive Procedure ;
| - 56. Dexamethasone/Pegaspargase/Vincristine
- (UMLS (NCI) C0338244) =Therapeutic or Preventive Procedure
|
- 15. Dexamethasone/Doxorubicin/Quinine/Verapamil/Vincristine
- (UMLS (NCI) C0280852) =Therapeutic or Preventive Procedure
| - 57. Dexamethasone/Phenylbutyrate/Sargramostim
- (UMLS (NCI) C0935673) =Therapeutic or Preventive Procedure
|
- 16. Dexamethasone/Doxorubicin/Thalidomide
- (UMLS (NCI) C0935753) =Therapeutic or Preventive Procedure
| - 58. Dexamethasone/Rituximab
- (UMLS (NCI) C0796452) DM/MOAB IDEC-C2B8;
=Therapeutic or Preventive Procedure |
- 17. Dexamethasone/Doxorubicin/Thalidomide/Vincristine
- (UMLS (NCI) C1327876) =Therapeutic or Preventive Procedure ;
| - 59. Dexamethasone/SU5416
- (UMLS (NCI) C0879617) =Therapeutic or Preventive Procedure
|
- 18. Dexamethasone/Doxorubicin/Verapamil/Vincristine
- (UMLS (NCI) C0280698) =Therapeutic or Preventive Procedure
| - 60. Dexamethasone/Thalidomide
- (UMLS (NCI) C1134614) =Therapeutic or Preventive Procedure ;
|
- 19. Dexamethasone/Doxorubicin/Vincristine
- (UMLS (NCI) C0077973) =Therapeutic or Preventive Procedure ;
| - 61. Dexamethasone/Vincristine
- (UMLS (NCI) C0281561) =Therapeutic or Preventive Procedure ;
|
- 20. Dexamethasone/Epoetin Alfa
- (UMLS (NCI) C1327965) =Therapeutic or Preventive Procedure ;
| - 62. Dexasone
- (UMLS (NCI) C0701253) =Steroid; Pharmacologic Substance
|
- 21. Dexamethasone/Etoposide/Ifosfamide
- (UMLS (NCI) C0879566) =Therapeutic or Preventive Procedure
| - 63. DEXBROMPHENIRAMINE
- [An alkylamine derivative with anticholinergic and sedative properties. Dexbrompheniramine is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of gastrointestinal smooth muscle. ( NCI )] (UMLS (NCI) C0057605) =Organic Chemical; Pharmacologic Substance ;
=BROMPHENIRAMINE;
[AH400] ANTIHISTAMINES, ALKYLAMINE =Dexbrompheniramine Maleate;
DEXBROMPHENIRAMINE 3 MG;
|
- 22. Dexamethasone/Etoposide/Ifosfamide/Methotrexate/Pegaspargase/Vincristine
- (UMLS (NCI) C0281684) =Therapeutic or Preventive Procedure
| - 64. Dexbrompheniramine Maleate
- [The maleate salt form of dexbrompheniramine, an alkylamine derivative with anticholinergic and sedative properties. Dexbrompheniramine is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of gastrointestinal smooth muscle. ( NCI )] (UMLS (NCI) C0113291) =Organic Chemical; Pharmacologic Substance =DEXBROMPHENIRAMINE;
=DEXBROMPHENIRAMINE MALEATE 2 MG;
DEXBROMPHENIRAMINE MALEATE 6 MG;
|
- 23. Dexamethasone/Etoposide/Ifosfamide/Pegaspargase/Vincristine
- (UMLS (NCI) C0392949) =Therapeutic or Preventive Procedure
| - 65. DEXCHLORPHENIRAMINE
- [An alkylamine, and first-generation histamine antagonist with anti-allergic activity. Dexchlorpheniramine competitively blocks H1 receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries and gastrointestinal (GI) smooth muscle. The antagonistic action of this agent blocks the activities of endogenous histamine, thereby preventing histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms. ( NCI )] (UMLS (NCI) C0057606) =Organic Chemical; Pharmacologic Substance ;
=chlorphenamine;
[AH400] ANTIHISTAMINES, ALKYLAMINE =(+)-2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine Maleate(1:1);
|
- 24. Dexamethasone/Floxuridine
- (UMLS (NCI) C0935752) =Therapeutic or Preventive Procedure
| - 66. dexedrine
- [ ] (UMLS (CSP) C0591355) =Organic Chemical; Pharmacologic Substance ;
|
- 25. Dexamethasone/Floxuridine/Leucovorin Calcium/SCH-58500
- (UMLS (NCI) C0879305) =Therapeutic or Preventive Procedure
| - 67. Dexmethylphenidate
- [The d-threo-enantiomer of methylphenidate, a central nervous system stimulant, appearing to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extracellular space. The mechanism of action in Attention Deficit Hyperactivity Disorder is unknown. (NCI) ( NCI )] (UMLS (NCI) C1169997) DEXMETHYLPHENIDATE PREPARATION =Organic Chemical; Pharmacologic Substance ;
=[CN802] AMPHETAMINE-LIKE STIMULANTS;
Unclassified Ingredients =DEXMETHYLPHENIDATE 2.5 MG;
DEXMETHYLPHENIDATE 5 MG;
DEXMETHYLPHENIDATE 10 MG;
|
- 26. Dexamethasone/Floxuridine/Mitomycin
- (UMLS (NCI) C0281389) =Therapeutic or Preventive Procedure ;
| - 68. Dexniguldipine
- [Dexniguldipine is the (+)-enantiomer of the dihydropyridine derivate niguldipine. Dexniguldipine showed a binding affinity to the P-glycoprotein and therefore it is to be assumed to block the P-glycoprotein pumping mechanism and to modulate multidrug resistance. (NCI) ( NCI )] (UMLS (NCI) C0208704) =Organic Chemical; Pharmacologic Substance ;
|
- 27. Dexamethasone/Fludarabine/Mitoxantrone
- (UMLS (NCI) C0393032) =Therapeutic or Preventive Procedure
| - 69. Dexoxadrol
- (UMLS (NCI) C0057609) =Organic Chemical; Pharmacologic Substance ;
|
- 28. Dexamethasone/Fludarabine/Pixantrone/Rituximab
- (UMLS (NCI) C1327857) =Therapeutic or Preventive Procedure
| - 70. dexpropranolol
- [ ] (UMLS (CSP) C0011792) =Organic Chemical; Pharmacologic Substance ;
|
- 29. Dexamethasone/Granisetron
- (UMLS (NCI) C0678002) =Therapeutic or Preventive Procedure
| - 71. Dexrazoxane Hydrochloride
- [The hydrochloride salt of a bisdioxopiperazine with cardioprotective and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, thereby preventing the metal-catalyzed formation of reactive oxygen radicals produced by anthracycline antibiotics such as doxorubicin. This agent also inhibits the catalytic activity of topoisomerase II, resulting in cell growth inhibition. ( NCI )] (UMLS (NCI) C0982118) DEXRAZOXANE HYDROCHLORIDE PREPARATION =Organic Chemical; Pharmacologic Substance =(+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione);
=DEXRAZOXANE HYDROCHLORIDE 250 MG;
DEXRAZOXANE HYDROCHLORIDE 500 MG;
|
- 30. Dexamethasone/Idarubicin
- (UMLS (NCI) C0935662) =Therapeutic or Preventive Procedure
| - 72. Dexrazoxane/Doxorubicin/Ifosfamide
- (UMLS (NCI) C0796700) =Therapeutic or Preventive Procedure ;
|
- 31. Dexamethasone/Idarubicin/Ifosfamide/Methotrexate/Thioguanine/Vincristine
- (UMLS (NCI) C0281687) =Therapeutic or Preventive Procedure
| - 73. Dextran Sulfate
- [Long-chain polymer of glucose containing 17-20% sulfur. It has been used as an anticoagulant and also has been shown to inhibit the binding of HIV-1 to CD4-POSITIVE T-LYMPHOCYTES. It is commonly used as both an experimental and clinical laboratory reagent and has been investigated for use as an antiviral agent, in the treatment of hypolipidemia, and for the prevention of free radical damage, among other applications. ( MSH )] (UMLS (NCI) C0079224) =Carbohydrate; Pharmacologic Substance ;
|
- 32. Dexamethasone/Idarubicin/Imatinib Mesylate/Pegaspargase/Vincristine
- (UMLS (NCI) C1327814) =Therapeutic or Preventive Procedure ;
| - 74. Dextran Sulfate Sodium
- [The sodium salt of sulfuric acid esters of glucose polymers. Dextran is produced by the action of the bacterium Leuconostoc mesenteroides and of other microorganisms on sucrose. This agent possesses strong hydrophilic properties and binds to various membranes, particularly those with a positive charge. (NCI04) ( NCI )] (UMLS (NCI) C0079225) =Carbohydrate; Pharmacologic Substance ;
|
- 33. Dexamethasone/Idarubicin/Pegaspargase/Vincristine
- (UMLS (NCI) C1327817) =Therapeutic or Preventive Procedure ;
| - 75. Dextroamphetamine Saccharate
- [The saccharate salt form of the dextro-isomer of amphetamine, a synthetic substance related to natural sympathomimetic amines, with CNS stimulating properties. Dextroamphetamine saccharate acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from its storage sites in nerve terminals in the brain, and inhibits their uptake within the mesocorticolimbic system, a major component of the brain reward system, thereby resulting in measurable behavioral changes such as euphoria. As a CNS stimulant, this agent may increase blood pressure and reduce appetite. Similar to other amphetamines, dextroamphetamine has a high potential for abuse, dependence, and addiction if used in large doses over extended periods of time. ( NCI )] (UMLS (NCI) C0724568) DEXTROAMPHETAMINE SACCHARATE PREPARATION;
=Organic Chemical; Pharmacologic Substance ;
=Dextroamphetamine;
=DEXTROAMPHETAMINE SACCHARATE 5 MG;
DEXTROAMPHETAMINE SACCHARATE 7.5 MG;
DEXTROAMPHETAMINE SACCHARATE 1.25 MG;
|
- 34. Dexamethasone/Imatinib Mesylate/Mercaptopurine/Methotrexate/Vincristine
- (UMLS (NCI) C1134462) =Therapeutic or Preventive Procedure
| - 76. Dextroamphetamine-Amphetamine
- [A combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur. (NCI04) ( NCI )] (UMLS (NCI) C0795571) =Organic Chemical; Pharmacologic Substance
|
- 35. Dexamethasone/Interferon Alfa
- (UMLS (NCI) C0338184) =Therapeutic or Preventive Procedure ;
| - 77. dextromethorphan
- [A synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex. ( NCI )] (UMLS (CSP) C0011816) =Organic Chemical; Pharmacologic Substance ;
=LEVORPHANOL;
morphinan;
[RE302] NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;
=DEXTROMETHORPHAN HYDROBROMIDE;
Dextromethorphan 1 MG/ML;
Dextromethorphan 1.5 MG/ML;
DEXTROMETHORPHAN 15 MG;
DEXTROMETHORPHAN 15 MG/5ML;
DEXTROMETHORPHAN 60 MG;
DEXTROMETHORPHAN 30 MG;
DEXTROMETHORPHAN 25 MG/5ML;
|
- 36. Dexamethasone/Isotretinoin
- (UMLS (NCI) C0935885) =Therapeutic or Preventive Procedure
| - 78. Dextropropoxyphene Hydrochloride
- [The hydrochloride salt form of dextropropoxyphene, the d-isomer of propoxyphene, a synthetic diphenyl propionate derivative, with narcotic analgesic effect. Mimics the effects of endogenous opiates, dextropropoxyphene, binds to mu receptors located throughout the central nervous system. The binding results in GTP to GDP exchanges on the mu-G-protein complex, through which inactivates effector adenylate cyclase thereby decreases intracellular cAMP. This inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin and somatostatin. In addition, dextropropoxyphene closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization, thereby reducing neuronal excitability which further decreases the perception of pain. ( NCI )] (UMLS (NCI) C0242451) =Organic Chemical; Pharmacologic Substance =PROPOXYPHENE;
Propoxyphene Napsylate =PROPOXYPHENE HYDROCHLORIDE 65 MG;
PROPOXYPHENE HYDROCHLORIDE 32 MG;
|
- 37. Dexamethasone/Melphalan
- (UMLS (NCI) C0338234) =Therapeutic or Preventive Procedure
| - 79. Dextrose Anhydrous
- [The anhydrous form of D-glucose, a natural monosaccharide and carbohydrate. Dextrose serves to replenish lost nutrients and electrolytes. The agent provides metabolic energy and is the primary ingredient in oral rehydration salts (ORS) and is used in intravenous (IV) fluids to provide nutrients to patients under intensive care who are unable to receive them by the oral route. Solutions containing dextrose restore blood glucose levels and provide calories and may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose anhydrous also plays a role in the production of proteins and in lipid metabolism. ( NCI )] (UMLS (NCI) C1165353) DEXTROSE, ANHYDROUS =Carbohydrate; Pharmacologic Substance
|
- 38. Dexamethasone/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine
- (UMLS (NCI) C0281126) =Therapeutic or Preventive Procedure
| - 80. DEXTROTHYROXINE
- [The dextrorotary isomer of thyroxine, a thyroid hormone with antihyperlipidemic activity. Dextrothyroxine stimulates the formation of low-density lipoprotein (LDL) and increases the catabolism of LDL thereby leading to increased excretion of cholesterol and bile acids via the biliary route. This results in a reduction in serum cholesterol and LDL. ( NCI )] (UMLS (NCI) C0011824) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Hormone =[CV350] ANTILIPEMIC AGENTS;
Levothyroxine =DEXTROTHYROXINE SODIUM;
|
- 39. Dexamethasone/Mercaptopurine/Methotrexate/Vincristine
- (UMLS (NCI) C0281127) =Therapeutic or Preventive Procedure
| - 81. Dexverapamil
- [The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. (NCI04) ( NCI )] (UMLS (NCI) C0280858) =Organic Chemical; Pharmacologic Substance
|
- 40. Dexamethasone/Mercaptopurine/Vincristine
- (UMLS (NCI) C0281217) =Therapeutic or Preventive Procedure ;
| - 82. Dexverapamil/Doxorubicin
- (UMLS (NCI) C0281757) =Therapeutic or Preventive Procedure
|
- 41. Dexamethasone/Methotrexate
- (UMLS (NCI) C0796531) DM/MTX =Therapeutic or Preventive Procedure ;
| - 83. Dexverapamil/Paclitaxel
- (UMLS (NCI) C0281326) =Therapeutic or Preventive Procedure
|
- 42. Dexamethasone/Methotrexate/Pegaspargase/Vincristine
- (UMLS (NCI) C0392950) =Therapeutic or Preventive Procedure
| - 84. Dexverapamil/Vinblastine
- (UMLS (NCI) C0281668) =Therapeutic or Preventive Procedure
|
home
